Dexmedetomidine Transdermal Systems (DMTS) is a novel transdermal patch formulation being developed by Teikoku Pharma USA, Inc. for the treatment of agitation associated with Alzheimer's disease. This Phase 2 clinical trial (NCT06052254) evaluates the efficacy and safety of dexmedetomidine delivered through a transdermal patch system — representing a completely novel approach to treating agitation in dementia patients.
Unlike traditional pharmacological treatments for agitation (antipsychotics, benzodiazepines), dexmedetomidine works through alpha-2 adrenergic receptor agonism, providing a non-sedating, non-dopaminergic mechanism that may avoid the significant risks associated with antipsychotic use in dementia patients.
| Attribute | Details |
|---|---|
| NCT Number | NCT06052254 |
| Sponsor | Teikoku Pharma USA, Inc. |
| Drug | Dexmedetomidine Transdermal System (DMTS) |
| Phase | Phase 2 |
| Indication | Agitation Associated with Dementia of the Alzheimer's Type |
| Status | Recruiting |
| Participants | 150 |
| Study Start | September 2025 |
| Estimated Completion | January 2027 |
| Design | Double-blind, placebo-controlled, randomized 1:1:1 |
Dexmedetomidine is a highly selective alpha-2 adrenergic receptor agonist with an alpha-2:alpha-1 selectivity ratio of approximately 1600:1. This selectivity is significantly higher than clonidine (alpha-2:alpha-1 ratio of ~200:1), making dexmedetomidine the most selective alpha-2 agonist available clinically[1].
The alpha-2 adrenergic system plays a critical role in modulating arousal, stress response, and behavioral agitation:
Noradrenergic dysregulation: In Alzheimer's disease, the locus coeruleus — the primary source of norepinephrine in the brain — undergoes significant degeneration. This leads to dysregulated norepinephrine signaling that may contribute to agitation and neuropsychiatric symptoms.
Hyperarousal state: Excessive noradrenergic activity in specific brain regions (prefrontal cortex, amygdala) is associated with agitation, aggression, and anxiety in dementia.
Non-dopaminergic mechanism: Unlike antipsychotics that primarily block dopamine receptors, alpha-2 agonism reduces agitation through a completely different pathway, potentially avoiding:
The transdermal formulation offers several unique advantages over intravenous dexmedetomidine used in ICU settings[2]:
| Phase | Duration | Description |
|---|---|---|
| Screening | Up to 21 days | Eligibility assessment |
| Baseline | Day -4 to Day -1 | Agitation assessment period |
| Treatment Period 1 | 4 days (96 hours) | First patch application |
| Washout | 14 days | Observation period |
| Treatment Period 2 | 4 days (96 hours) | Second application (if eligible) |
| Follow-up | Ongoing | Safety monitoring |
The trial randomizes participants 1:1:1 to three arms:
Change in Agitated Behavior Scale (ABS) total score from baseline (Day -4 to Day -1 mean) to 96 hours post-first application (Day 1 to Day 4).
The ABS is a 14-item scale measuring:
| Measure | Timepoint | Description |
|---|---|---|
| CGI-S Change | Day 5 | Clinical Global Impression - Severity |
| ABS Change | Day 7 | 168-hour post-application |
| CGI-S Change | Day 8 | Extended observation |
| NPI-NH Change | Day 7 | Neuropsychiatric Inventory - Nursing Home Version |
| Second Dosing Eligibility | Day 15 | Criteria for repeat treatment |
Agitation affects up to 70% of Alzheimer's disease patients during their disease course and represents one of the most challenging neuropsychiatric symptoms[3]:
| Treatment Class | Mechanism | Key Limitations |
|---|---|---|
| Atypical Antipsychotics | D2/5-HT2 antagonism | Stroke risk, mortality warning, metabolic effects |
| Typical Antipsychotics | D2 antagonism | Extrapyramidal symptoms, sedation |
| Benzodiazepines | GABA-A modulation | Falls, cognitive worsening, dependence |
| Mood Stabilizers | Various | Limited efficacy, toxicity |
Based on intravenous and oral formulations:
| Drug | Company | Mechanism | Phase | Status |
|---|---|---|---|---|
| KarXT (xanomeline/trospium) | BMS | M1/M4 muscarinic agonist | Phase 3 | Recruiting |
| Dexmedetomidine DMTS | Teikoku Pharma | Alpha-2 agonist | Phase 2 | Recruiting |
| Masupirdine (SUVN-502) | Suven | 5-HT6 antagonist | Phase 2 | Completed |
| Nabilone | Various | CB1/CB2 agonist | Phase 2/3 | Various |
| Methylphenidate | Various | Dopamine reuptake | Phase 3 | Completed |
Dexmedetomidine: A selective alpha-2 agonist for sedation. J Clin Pharmacol. 2018. ↩︎
Transdermal drug delivery: principles and applications. Adv Drug Deliv Rev. 2021. ↩︎
Agitation in Alzheimer's disease: prevalence and management. CNS Drugs. 2023. ↩︎